Christopher Berger, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address1001 Potrero Avenue, #5J4
San Francisco CA 94110
ORCID ORCID Icon0000-0002-0034-7544 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Pittsburgh, Pittsburgh, PA USAB.Phil12/2006International Health
    Universitat Autònoma de Barcelona (UAB), Barcelona, SpainMasters in Tropical Medicine and International Health06/2007Tropical Medicine and International Health
    University of Pittsburgh, Pittsburgh, PA USAMD05/2012Medicine
    University of California San Francisco (UCSF), San Francisco, CA USA06/2015Internal Medicine Residency
    University of California San Francisco (UCSF), San Francisco, CA USA07/2019Fellowship in Pulmonary and Critical Care Medicine

    Collapse Overview 
    Collapse Overview
    Christopher Berger, MD, MSIMT is an assistant professor in the UCSF Division of Pulmonary Critical Care Medicine, clinically based at Zuckerberg San Francisco General Hospital. His research focuses on improving tuberculosis screening, diagnosis, and treatment programs globally through the use of implementation science and human-centered design principles. He works with Dr. Adithya Cattamanchi on projects in the Philippines to improve the diagnostic and clinical tools used in MDR and XDR TB and in Uganda designing improved versions of the globally utilized “Directly Observed Therapy” toolkit. Christopher completed his undergraduate degree in international health at the University of Pittsburgh where he went on complete his MD. He received his master’s in tropical medicine and international health at the Universitat Autonoma de Barcelona in Barcelona, Spain. He completed his internal medicine residency and pulmonary/critical care medicine fellowship at UCSF. He is currently completing a masters in Clinical Research at UCSF.
    Collapse Global Health Equity

    Collapse Research 
    Collapse Research Activities and Funding
    Digital adherence technologies to facilitate completion of short-course tuberculosis preventive therapy among people living with HIV
    NIH K23HL156784Sep 8, 2021 - Aug 31, 2026
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda. PLOS Digit Health. 2023 Jun; 2(6):e0000138. Kiwanuka N, Kityamuwesi A, Crowder R, Guzman K, Berger CA, Lamunu M, Namale C, Kunihira Tinka L, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Patel D, Sammann A, Turyahabwe S, Dowdy DW, Katamba A, Cattamanchi A. PMID: 37390077; PMCID: PMC10313004.
      View in: PubMed   Mentions: 1  
    2. Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda. Int J Tuberc Lung Dis. 2023 06 01; 27(6):458-464. Sung J, Musinguzi A, Kadota JL, Baik Y, Nabunje J, Welishe F, Bishop O, Berger CA, Katahoire A, Nakitende A, Nakimuli J, Akello L, Kasidi JR, Kunihira Tinka L, Kamya MR, Sohn H, Kiwanuka N, Katamba A, Cattamanchi A, Dowdy DW, Semitala FC. PMID: 37231600; PMCID: PMC10316532.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Barriers and Facilitators to Implementing a Digital Adherence Technology for Tuberculosis Treatment Supervision in Uganda: Qualitative Study. J Med Internet Res. 2023 05 30; 25:e38828. Leddy A, Ggita J, Berger CA, Kityamuwesi A, Sanyu AN, Tinka LK, Crowder R, Turyahabwe S, Katamba A, Cattamanchi A. PMID: 37252774; PMCID: PMC10265431.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Adherence trajectory as an on-treatment risk indicator among drug-resistant TB patients in the Philippines. PLoS One. 2022; 17(11):e0277078. Huddart S, Geocaniga-Gaviola DM, Crowder R, Lim AR, Lopez E, Valdez CL, Berger CA, Destura R, Kato-Maeda M, Cattamanchi A, Garfin AMC. PMID: 36346814; PMCID: PMC9642894.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 12; 18(12):e1003875. Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. PMID: 34914696; PMCID: PMC8726462.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives. Implement Sci Commun. 2021 Jun 30; 2(1):71. Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, Berger CA, Katamba A, Kiwanuka N, Kamya MR, Dowdy D, Cattamanchi A, Katahoire AR. PMID: 34193311; PMCID: PMC8247167.
      View in: PubMed   Mentions: 4  
    7. Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda. PLoS Med. 2021 05; 18(5):e1003628. Cattamanchi A, Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka LK, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Berger C, Tucker A, Patel D, Sammann A, Turyahabwe S, Dowdy D, Katamba A. PMID: 33956802; PMCID: PMC8136841.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    8. Iterative Adaptation of a Tuberculosis Digital Medication Adherence Technology to Meet User Needs: Qualitative Study of Patients and Health Care Providers Using Human-Centered Design Methods. JMIR Form Res. 2020 Dec 08; 4(12):e19270. Patel D, Berger CA, Kityamuwesi A, Ggita J, Kunihira Tinka L, Turimumahoro P, Feler J, Chehab L, Chen AZ, Gupta N, Turyahabwe S, Katamba A, Cattamanchi A, Sammann A. PMID: 33289494; PMCID: PMC7755538.
      View in: PubMed   Mentions: 6  
    9. Study protocol and implementation details for a pragmatic, stepped-wedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion. BMJ Open. 2020 11 27; 10(11):e039895. Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka LK, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Berger CA, Tucker A, Patel D, Sammann A, Dowdy D, Stavia T, Cattamanchi A, Katamba A. PMID: 33247012; PMCID: PMC7703448.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    10. Opportunities to improve digital adherence technologies and TB care using human-centered design. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1112-1115. Berger C, Patel D, Kityamuwesi A, Ggita J, Tinka LK, Turimumahoro P, Neville K, Chehab L, Chen AZ, Gupta N, Turyahabwe S, Katamba A, Cattamanchi A, Sammann A. PMID: 33126949; PMCID: PMC9094398.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    11. Variation in tuberculosis treatment outcomes and treatment supervision practices in Uganda. J Clin Tuberc Other Mycobact Dis. 2020 Dec; 21:100184. Berger CA, Kityamuwesi A, Crowder R, Lamunu M, Kunihira Tinka L, Ggita J, Sanyu Nakate A, Namale C, Oyuku D, Chen K, Turyahabwe S, Cattamanchi A, Katamba A. PMID: 33204851; PMCID: PMC7648165.
      View in: PubMed   Mentions: 4  
    12. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020 08 12; 15(1):65. Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. PMID: 32787925; PMCID: PMC7425004.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    13. Summary for Clinicians: 2019 Clinical Practice Guideline Summary for the Treatment of Drug-Resistant Tuberculosis. Ann Am Thorac Soc. 2020 08; 17(8):911-917. Berger CA, Alipanah N, Kheir F, Ruminjo JK, Nahid P, Thomson C. PMID: 32464069.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    14. Willingness to accept reimbursement for visits to an HIV clinic for tuberculosis preventive therapy. Int J Tuberc Lung Dis. 2020 07 01; 24(7):729-731. Kadota JL, Katamba A, Musinguzi A, Welishe F, Nabunje J, Ssemata JL, Berger CA, Kamya MR, Namusobya J, Semitala FC, Cattamanchi A, Dowdy DW. PMID: 32718409; PMCID: PMC7891860.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    15. Management and Outcomes of Critically-III Patients with COVID-19 Pneumonia at a Safety-net Hospital in San Francisco, a Region with Early Public Health Interventions: A Case Series. medRxiv. 2020 May 29. Vanderburg S, Alipanah N, Crowder R, Yoon C, Wang R, Thakur N, Slown K, Shete PB, Rofael M, Metcalfe JZ, Merrifield C, Marquez C, Malcolm K, Lipnick M, Jain V, Gomez A, Burns G, Brown LB, Berger C, Auyeung V, Cattamanchi A, Hendrickson CM. PMID: 32511538; PMCID: PMC7273306.
      View in: PubMed   Mentions:
    16. Presentation and outcome of suspected sepsis in a high-HIV burden, high antiretroviral coverage setting. Int J Infect Dis. 2020 Jul; 96:276-283. Chaka W, Berger C, Huo S, Robertson V, Tachiona C, Magwenzi M, Magombei T, Mpamhanga C, Katzenstein D, Metcalfe J. PMID: 32289564; PMCID: PMC8040698.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. J Clin Tuberc Other Mycobact Dis. 2020 Feb; 18:100136. Cattamanchi A, Berger CA, Shete PB, Turyahabwe S, Joloba M, Moore DA, Davis LJ, Katamba A. PMID: 31879703; PMCID: PMC6920311.
      View in: PubMed   Mentions: 12  
    18. Open-source point-of-care electronic medical records for use in resource-limited settings: systematic review and questionnaire surveys. BMJ Open. 2012; 2(4). Millard PS, Bru J, Berger CA. PMID: 22763661; PMCID: PMC3391372.
      View in: PubMed   Mentions: 13     Fields:    
    Christopher's Networks
    Concepts (41)
    Derived automatically from this person's publications.
    Co-Authors (24)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department